Myocardial Involvement of Severe Acute Respiratory Syndrome-Cov-2 (Covid19) Infected Patients

Imaging Cardiac Phenotype of SARS-Cov-2 (Covid19) Infected Patients

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT04358952

Acronym

COCARDE

Enrollment

122

Registered

2020-04-24

Start date

2020-04-04

Completion date

2021-04-02

Last updated

2021-06-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cardiomyopathies

Keywords

Left ventricular systolic function, left ventricular diastolic function, global longitudinal strain, SARS-Cov-2, Covid-19

Brief summary

The effects of severe acute respiratory syndrome SARS-Cov-2 (Covid-19) on the myocardium and their role in the clinical course of infected patients are still unknown. Epidemiological studies report biological myocardial involvement in 10 to 25% of cases. The objective of this study is to cardiac phenotype using comprehensive cardiac imaging tools of patients infected with Covid 19 in order to explore the functional impact of the infection on the myocardium.

Detailed description

A large population of Covid 19 infected patients of different ages and severity levels will be explored by transthoracic echocardiography with measurement of myocardial functional parameters such as ejection fraction, longitudinal strain and relaxation parameters and will be compared to an uninfected population paired for age and sex. Patients with biological myocardial involvement will be followed to determine the evolution of their myocardial functional parameters during the course of the infection.

Interventions

DIAGNOSTIC_TESTGlobal Longitudinal Strain

Electrocardiogram with measure of the Global Longitudinal Strain to evaluate myocardiac dysfunction

Study design

Observational model

OTHER

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Major patients hospitalized for respiratory criteria for SARS-Cov-2 infection confirmed by RT-PCR

Exclusion criteria

* Underage patients. Patients refusing to participate in research. Patients with a history of heart disease.

Design outcomes

Primary

Measure	Time frame	Description
Left ventricular function	Day 0	Left ventricular function evaluated by global longitudinal strain

Secondary

Measure	Time frame	Description
inflammatory biological parameters	Day 0	Cytokine rate

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 14, 2026